WO2007085681A1 - Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium - Google Patents

Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium Download PDF

Info

Publication number
WO2007085681A1
WO2007085681A1 PCT/FI2006/000394 FI2006000394W WO2007085681A1 WO 2007085681 A1 WO2007085681 A1 WO 2007085681A1 FI 2006000394 W FI2006000394 W FI 2006000394W WO 2007085681 A1 WO2007085681 A1 WO 2007085681A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
treatment substance
magnesium sulfate
warts
magnesium salts
Prior art date
Application number
PCT/FI2006/000394
Other languages
English (en)
Inventor
Kari Honkanen
Original Assignee
Medgenerics Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medgenerics Oy filed Critical Medgenerics Oy
Priority to EP06820070A priority Critical patent/EP1976540A4/fr
Publication of WO2007085681A1 publication Critical patent/WO2007085681A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates on the one hand to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate, and on the other hand to a novel use of magnesium sulfate.
  • Warts (Verruca vulgaris) are tumor-like changes in the skin and believed to be caused especially by Papilloma virus. Warts may appear in various parts of the body, but mostly in the hands and feet. School children are particularly susceptible to developing warts, becoming exposed in their gymnastic/exercise activities, swimming pools, shower facilities, etc.
  • warts are most commonly attended locally, e.g. by means of salicylic-acid containing bandaids and solutions, deep freezing, laser, surgery or electric needle treatments .
  • the foregoing type of therapies usually necessitate the individual treatment of each wart, as a result of which a plurality of treatments are occasionally necessary, depending on the type of therapy and the number of warts.
  • the results involve practically always cosmetic flaws, necessitating a meticulous postoperative care to avoid infections and to achieve a full recovery of the skin following a wart removal .
  • the current treatments of warts often involve not only cosmetic flaws but also outright pains. In the event that warts develop in abundance, the above type of treatments become impossible to conduct in a single session but, instead, the removal of warts must be sequenced over a longer period of time unless the warts disappear by themselves after starting the removal process.
  • Magnesium-containing products have been used in various therapies, e.g. as antacids, laxative and purgative preparations, but also as anticonvulsants and sedatives .
  • the publication DE 19541735 discloses a solution, which is intended for the use of hydrothermal composite preparations, containing not only magnesium but also numerous other ingredients, in the treatment of e.g. skin problems, warts, orange-peel skin, psoriasis, acne, etc., not only by subcutaneous application but also in the form of e.g. bath salts, soaps, lotions, massage oils, sun screens, etc., or else e.g. in the form of tablets or solutions for oral administration.
  • Prior known are also a plurality of magnesium-sulfate containing compositions for internal dosage.
  • Orally administered compositions for removing warts have been described e.g. in the International patent publication WO 99/38517.
  • the objective in using a treatment substance of the invention, containing magnesium salts, and in using magnesium sulfate is to provide a decisive improvement regarding the above problems and to thereby raise substantially the existing state of the art.
  • the features, principally characteristic of a treatment substance of the invention, containing magnesium salts, and of a novel use of magnesium sulfate are presented in the characterizing clauses of the independent claims directed to two alternative implementations of each of them.
  • a treatment substance of the invention and a novel application of magnesium sulfate enable a rapid and safe therapy, particularly for the removal of warts by the activity of an internally administered, magnesium-sulfate based treatment substance without a risk of the treatment causing e.g. swallowing, gullet or gastric trouble for a person being attended.
  • the therapy conducted with a treatment substance of the invention provides positive results with extremely slight or totally without side effects over a treatment period which in the best case scenario is less than a week, the treatment resulting in a simultaneous disappearance of warts from the patient's skin, even from various extremities.
  • a trouble-free repetition of the therapy, conducted with a treatment substance of the invention is also possible in the event that warts reoccurring.
  • a principal benefit offered by the invention lies in the fact that a treatment substance, which lends itself to easy and agreeable internal administration, enables a simultaneous treatment of warts present even in various parts of the body, the warts disappearing by themselves during the course of the treatment with no need for after-care and/or corrective measures of the skin that are usually required in local treatments.
  • the invention relates first of all to a treatment substance containing magnesium salts for the treatment of tumors or the like, the treatment substance, used particularly for removing warts internally, being based, as regards its active ingredient, essentially on magnesium sulfate.
  • the treatment substance is formulated for anal administration, such as in the form of a suppository or the like. This enables avoiding the problems caused by oral administration of the treatment substance.
  • the single dose of magnesium sulfate delivered by the treatment substance is 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.
  • the treatment substance is formulated for a solution administered as a subcutaneous or submucuous injection.
  • a solution administered as a subcutaneous or submucuous injection is formulated for a solution administered as a subcutaneous or submucuous injection.
  • the invention relates also to the use of magnesium sulfate by anal administration, such as in the form of a suppository or the like, in the manufacture of a treatment substance used particularly for the removal of warts .
  • the invention relates to the use of magnesium sulfate in the manufacture of a treatment substance, the single dose of magnesium sulfate delivered thereby being 715-1200, most preferably 950 g, administered three times a day for the period of at least a week.
  • the invention enables the use of magnesium sulfate also in the manufacture of a solution for administration as a subcutaneous or submucuous injection, particularly for the removal of warts.
  • the therapy enabled by the invention has been subjected to practical testing, specifically by using a treatment solution with 20 g of magnesium sulfate and 280 ml of purified water .
  • the test group was divided in two, the first faction being treated with a magnesium-sulfate based treatment substance and the second faction with a placebo treatment.
  • the therapy was conducted with identical single doses for each group in either one- or two-week long treatment periods, after which it was verifiable that the magnesium-sulfate based therapy provided invariably a good result as all warts in the attended patients disappeared.
  • the therapy not a single cure of warts was found in the therapy given as a placebo treatment.
  • the patients of this second group were thereafter subjected to a therapy based on magnesium sulfate, the healing result was again positive as the warts disappeared in the best case in one and a half weeks.
  • the invention is not limited to the foregoing embodiments as it can be varied within the same basic concept, e.g. in such a way that the treatment substance includes suitable dyes, excipients and/or additives used as its per se inert ingredients.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne d'une part une substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires et, d'autre part, une nouvelle utilisation du sulfate de magnésium. La substance thérapeutique, utilisée notamment pour éliminer par voie interne des verrues, est essentiellement à base de sulfate de magnésium en tant que principe actif, la substance thérapeutique étant formulée pour l'administration par voie rectale, par exemple sous la forme d'un suppositoire ou similaire.
PCT/FI2006/000394 2006-01-24 2006-11-29 Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium WO2007085681A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06820070A EP1976540A4 (fr) 2006-01-24 2006-11-29 Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20060065 2006-01-24
FI20060065A FI119101B (fi) 2006-01-24 2006-01-24 Magnesiumsuoloja sisältävä hoitoaine kasvainten tai vastaavien hoitoon ja magnesiumsulfaatin käyttö

Publications (1)

Publication Number Publication Date
WO2007085681A1 true WO2007085681A1 (fr) 2007-08-02

Family

ID=35883876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2006/000394 WO2007085681A1 (fr) 2006-01-24 2006-11-29 Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium

Country Status (3)

Country Link
EP (1) EP1976540A4 (fr)
FI (1) FI119101B (fr)
WO (1) WO2007085681A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009798A1 (fr) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Melanges ou complexes contenant du calcium et du sulfate
WO1999038517A1 (fr) * 1998-01-30 1999-08-05 Bene Pharma Oy Compositions de traitement de verrues par voie orale
US6218192B1 (en) * 1991-04-08 2001-04-17 Research Foundation Of The State University Of New York Method and composition for treatment of headache using magnesium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1499984A (en) * 1975-04-16 1978-02-01 Unigate Foods Ltd Dietary foods
IT1272994B (it) * 1994-05-25 1997-07-01 Giampiero Valletta Uso di prodotti contenenti magnesio nella terapia e nella profilassi di malattie neoplastiche e di malattie di tipo autoimmunitario.-

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218192B1 (en) * 1991-04-08 2001-04-17 Research Foundation Of The State University Of New York Method and composition for treatment of headache using magnesium
WO1994009798A1 (fr) * 1992-10-29 1994-05-11 C-P Technology Limited Partnership Melanges ou complexes contenant du calcium et du sulfate
WO1999038517A1 (fr) * 1998-01-30 1999-08-05 Bene Pharma Oy Compositions de traitement de verrues par voie orale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1976540A4 *

Also Published As

Publication number Publication date
EP1976540A4 (fr) 2010-07-28
EP1976540A1 (fr) 2008-10-08
FI20060065A (fi) 2007-07-25
FI20060065A0 (fi) 2006-01-24
FI119101B (fi) 2008-07-31

Similar Documents

Publication Publication Date Title
US5589480A (en) Topical application of opioid analgesic drugs such as morphine
EA032439B1 (ru) Композиции и способы для лечения поверхностных ран
CN108853312A (zh) 聚桂醇外用凝胶及其制备方法
DK166479B (da) Anvendelse af fluoxetin, norfluoxetin eller et farmaceutisk acceptabelt salt af fluoxetin eller norfluoxetin til fremstilling af et laegemiddel med anxiolytisk virkning
RU2006139819A (ru) Применение симетикона для предрасположенных к запорам пациентов
US5278172A (en) Method and composition for treating tendon or joint inflammation using a vasodilator
CN102188572B (zh) 一种治疗骨伤的中药
CN103977194A (zh) 能有效治疗创面感染的外用药在制备治疗糖尿病足药物中的应用
US5576329A (en) Method for treating tendon or joint inflammation with papaverine HCL
CN109700856A (zh) 一种具有活血通络、舒筋止痛的中药外用方剂
EP2322177B1 (fr) Utilisation d'une préparation contenant de la nifédipine pour traiter le vaginisme
JPH08500343A (ja) セシウムイオンを用いた治療方法
EP1976540A1 (fr) Substance thérapeutique contenant des sels de magnésium pour le traitement de tumeurs ou similaires, et utilisation de sels de magnésium
CN1669562A (zh) 筋骨康复膏及其制备方法
CN103585257B (zh) 一种治疗骨折的中药散剂
CN102078516B (zh) 一种治疗骨伤的中药
CN102512650A (zh) 一种治疗面神经麻痹的外用药物
CN104056080A (zh) 一种治疗脑血栓后遗症的中药组合物
RU2357747C1 (ru) Способ лечения больных псориатической болезнью
RU2181995C1 (ru) Способ лечения миофасциального болевого синдрома
CN107569577A (zh) 一种药物组合物在制备治疗三叉神经痛的药物中的应用
CN103110748B (zh) 一种治疗性病的复方中药组合物及其用途
RU2200557C1 (ru) Способ лечения гипертрофических и келоидных рубцов
RU2182006C2 (ru) Способ лечения ревматоидного артрита
Efraimidis et al. Efficacy of laser application for the rehabilitation of patients with Bell's palsy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006820070

Country of ref document: EP